O uso profilático dos antimicrobianos é frequente na produção animal para a prevenção de infecções entéricas ou respiratórias de origem bacteriana, contudo, pouco se conhece a respeito do impacto dessa administração. Assim, o presente estudo avaliou o uso profilático de ceftiofur em leitões neonatos sobre a ocorrência de infecções, o desempenho, a frequência de dias com escore fecal alterado e a quantificação de bactérias eliminadas nas fezes na maternidade e na creche. Foram utilizados 174 leitões recém-nascidos divididos em dois tratamentos: Ceftiofur (CEF, 5 mL/kg, n=89) e Controle (CTR, solução salina tamponada, n=85), ambos administrados no primeiro dia de vida e pela via de intramuscular. O delineamento foi em blocos, sendo considerados a ordem de parto e o peso dos leitões como bloco e os dados foram submetidos à análise de variância, empregando-se o programa SAS (2002). O nível de significância considerado foi de 5%. Na maternidade, os leitões tratados com ceftiofur não apresentaram redução na ocorrência de infecções e na eliminação de bactérias nas fezes, assim como não houve maior frequência de escore fecal alterado. Verificou-se um aumento gradativo na eliminação de bactérias até o 14º dia de vida com posterior declínio (P<,0001). Já para o desempenho, os leitões que receberam o ceftiofur apresentaram peso superior aos 21 dias de idade (P=0,0002) e o ganho de peso superior (P<,0001) em relação ao controle. Esta última característica também aumentou com o avançar da idade (P<,0001). Na creche, o tratamento ceftiofur não foi capaz de influenciar a ocorrência de infecções, bem como não interferiu no escore fecal (P>0,005), no desempenho (P>0,005) e na quantificação de bactérias eliminadas (P=0,6833). Conclui-se que a administração profilática de ceftiofur no primeiro dia de vida do leitão não reduziu a ocorrência de infecções, não reduziu a frequência de dias com escore fecal alterado e os leitões não eliminaram menor quantidade de bactérias nas fezes na maternidade e na creche, contudo os leitões apresentaram melhor desempenho durante o aleitamento, mas não na fase de creche / Prophylactic use of antimicrobials is a widespread practice in livestock production as a therapy for enteric or respiratory bacterial infections, however, little is known regarding the consequences of this management. Thus, the aim of the present study was to evaluate the prophylactic use of ceftiofur on the occurrence of infections, performance, frequency of days with altered fecal score as well as the quantification of bacteria excreted through feces of suckling and nursery piglets. For this purpose, 174 newborn piglets were assigned to two treatments as follows: Ceftiofur (CEF, 5 mL/kg, n=89) and Control (CTR, tamponed saline solution, n=85), both administered intramuscularly on the first day of life. The experimental design was in blocks; parturition order and piglet weight was considered as one block. Data were subjected to analysis of variance using the SAS software (2002). At the level of 5% of significance. During the suckling period, piglets treated with ceftiofur showed no reduction in the occurrence of infections and the excretion of bacteria through feces; also the frequency of altered fecal score was unchanged. There was a gradual increase in fecal bacterial excretion until the 14th day of life, declining after this period (P<.0001). Regarding piglet performance, the group treated with ceftiofur were heavier at 21 days (P=0.0002) and had higher average daily gain (ADG) (P<.0001) compared to control. Moreover, ADG traits also increased concomitantly with the age (P<.0001). In nursery piglets, treatment with ceftiofur had no influence on the occurrence of infections, fecal score (P>0.005), performance (P>0.005) and quantification of excreted fecal bacteria (P=0.6833). In conclusion, prophylactic use of ceftiofur on the first day of the piglets life was not able to reduce the occurrence of infections, had no influence in the frequency of days with altered fecal score and piglets did not excreted fewer bacteria in feces, however, piglets showed better performance during the suckling period, but not in the nursery period

O uso profilático dos antimicrobianos é frequente na produção animal para a prevenção de infecções entéricas ou respiratórias de origem bacteriana, contudo, pouco se conhece a respeito do impacto dessa administração. Assim, o presente estudo avaliou o uso profilático de ceftiofur em leitões neonatos sobre a ocorrência de infecções, o desempenho, a frequência de dias com escore fecal alterado e a quantificação de bactérias eliminadas nas fezes na maternidade e na creche. Foram utilizados 174 leitões recém-nascidos divididos em dois tratamentos: Ceftiofur (CEF, 5 mL/kg, n=89) e Controle (CTR, solução salina tamponada, n=85), ambos administrados no primeiro dia de vida e pela via de intramuscular. O delineamento foi em blocos, sendo considerados a ordem de parto e o peso dos leitões como bloco e os dados foram submetidos à análise de variância, empregando-se o programa SAS (2002). O nível de significância considerado foi de 5%. Na maternidade, os leitões tratados com ceftiofur não apresentaram redução na ocorrência de infecções e na eliminação de bactérias nas fezes, assim como não houve maior frequência de escore fecal alterado. Verificou-se um aumento gradativo na eliminação de bactérias até o 14º dia de vida com posterior declínio (P<,0001). Já para o desempenho, os leitões que receberam o ceftiofur apresentaram peso superior aos 21 dias de idade (P=0,0002) e o ganho de peso superior (P<,0001) em relação ao controle. Esta última característica também aumentou com o avançar da idade (P<,0001). Na creche, o tratamento ceftiofur não foi capaz de influenciar a ocorrência de infecções, bem como não interferiu no escore fecal (P>0,005), no desempenho (P>0,005) e na quantificação de bactérias eliminadas (P=0,6833). Conclui-se que a administração profilática de ceftiofur no primeiro dia de vida do leitão não reduziu a ocorrência de infecções, não reduziu a frequência de dias com escore fecal alterado e os leitões não eliminaram menor quantidade de bactérias nas fezes na maternidade e na creche, contudo os leitões apresentaram melhor desempenho durante o aleitamento, mas não na fase de creche / Prophylactic use of antimicrobials is a widespread practice in livestock production as a therapy for enteric or respiratory bacterial infections, however, little is known regarding the consequences of this management. Thus, the aim of the present study was to evaluate the prophylactic use of ceftiofur on the occurrence of infections, performance, frequency of days with altered fecal score as well as the quantification of bacteria excreted through feces of suckling and nursery piglets. For this purpose, 174 newborn piglets were assigned to two treatments as follows: Ceftiofur (CEF, 5 mL/kg, n=89) and Control (CTR, tamponed saline solution, n=85), both administered intramuscularly on the first day of life. The experimental design was in blocks; parturition order and piglet weight was considered as one block. Data were subjected to analysis of variance using the SAS software (2002). At the level of 5% of significance. During the suckling period, piglets treated with ceftiofur showed no reduction in the occurrence of infections and the excretion of bacteria through feces; also the frequency of altered fecal score was unchanged. There was a gradual increase in fecal bacterial excretion until the 14th day of life, declining after this period (P<.0001). Regarding piglet performance, the group treated with ceftiofur were heavier at 21 days (P=0.0002) and had higher average daily gain (ADG) (P<.0001) compared to control. Moreover, ADG traits also increased concomitantly with the age (P<.0001). In nursery piglets, treatment with ceftiofur had no influence on the occurrence of infections, fecal score (P>0.005), performance (P>0.005) and quantification of excreted fecal bacteria (P=0.6833). In conclusion, prophylactic use of ceftiofur on the first day of the piglets life was not able to reduce the occurrence of infections, had no influence in the frequency of days with altered fecal score and piglets did not excreted fewer bacteria in feces, however, piglets showed better performance during the suckling period, but not in the nursery period

Le microbiote humain est défini par l’ensemble des microbes habitant un site corporel en particulier. Les différents microbiotes de l’Homme, notamment le microbiote intestinal qui est le plus étudié, peuvent moduler de nombreux mécanismes biologiques dont le métabolisme et la réponse immunitaire. Un débalancement du microbiote au niveau des espèces qui le composent, ou dysbiose, a été associé à plusieurs maladies inflammatoires comme le diabète, l’obésité, mais aussi divers types de cancer. De plus, il a été démontré que les bactéries pouvaient avoir un impact sur la réponse des patients aux thérapies contre le cancer. Le cancer du sein est le cancer le plus mortel chez la femme. Or, l’étiologie de la maladie reste incertaine. Récemment, il a été montré que des bactéries pouvaient infiltrer les tissus plus profonds comme le tissu mammaire, formant un microbiote local. Considérant l’impact que la dysbiose peut avoir sur la réponse immunitaire antitumorale et la réponse aux traitements, nous avons émis comme hypothèse qu’une présence bactérienne intratumorale similaire, en composition et en quantité, à celle du tissu normal non-cancéreux affecte la progression du cancer du sein ainsi que le devenir clinique des patientes. La présence du microbiote intratumoral du sein a donc été validée par la détection de plusieurs composants bactériens sur des coupes tumorales à l’aide de marquages moléculaires. Puis, nous avons évalué le rôle potentiel de ce microbiote en quantifiant et identifiant les espèces bactériennes présentes dans les tumeurs et les tissus normaux adjacents des patientes de notre cohorte du cancer du sein. Nos résultats montrent une abondance moins élevée de l’ADN bactérien dans les tumeurs du sein comparativement aux tissus normaux adjacents appariés, suggérant qu’une altération du microbiote mammaire est associée au cancer. De plus, les patientes ayant un signal bactérien très faible dans leur tumeur avaient un nombre de récidives plus élevé. Cette influence de la quantité apparente de bactéries sur le devenir clinique a été observée principalement chez les patientes ayant une tumeur avancée, soit un grade ou un stade élevé, et de sous-types moléculaires Luminal HER2+, HER2+ (non-luminal) et Luminal B. Aucune relation n’a été observée entre la composition bactérienne du microbiote intratumoral mammaire et la récidive. Nos travaux suggèrent une implication pronostique et thérapeutique de la charge bactérienne du microbiote associé aux tumeurs mammaires. / The human microbiota is defined by all the microbes inhabiting a specific body site. The different human microbiota, and in particular the intestinal microbiota which is the most studied, can modulate many biological mechanisms, including metabolism and the immune response. An imbalance in the bacterial species that compose the microbiota, or dysbiosis, has been associated with several inflammatory diseases such as diabetes, obesity, but also various types of cancer. Additionally, bacteria have been shown to impact the response of patients to cancer therapy. Breast cancer is the deadliest cancer in women. However, the etiology of the disease remains uncertain. Recently, it has been shown that bacteria can infiltrate deeper tissues like breast tissue, forming a local microbiota. Considering the impact that dysbiosis can have on the anti-tumor immune response and the response to treatments, we hypothesized that an intratumoral bacterial presence similar in composition and quantity to that of normal non-cancerous tissue affects the progression of breast cancer, as well as the clinical outcomes of patients. The presence of the intratumoral breast microbiota was therefore validated by the detection of several bacterial components on whole tumor sections using molecular staining. Then, we evaluated the potential role of this microbiota by quantifying and identifying the bacterial species present in tumors and adjacent normal tissues of patients in our breast cancer cohort. Our results show a lower abundance of bacterial DNA in breast tumors compared to adjacent paired normal tissues, suggesting that an alteration of the mammary microbiota is associated with breast cancer. In addition, patients with a very low bacterial signal in their tumor had a higher number of recurrences. This influence of the apparent quantity of bacteria on the clinical outcomes has been observed mainly in patients with an advanced tumor, either a high grade or a high stage, and of the Luminal HER2+, HER2+ (non-luminal) and Luminal B molecular subtype. No relationship has been observed between the bacterial composition of the breast intratumoral microbiota and the recurrence. Our work suggests a prognostic and therapeutic implication of the bacterial load of the microbiota associated with breast tumors.

No description available.